Crizotinib: In locally advanced or metastatic non-small cell lung cancer

被引：31

作者：

Monique P. Curran

机构：

[1] Adis A Wolters Kluwer Business, North Shore 0754, Auckland, 41 Centorian Drive

来源：

Drugs | 2012年 / 72卷 / 1期

关键词：

Adis-Drug-Profiles; Crizotinib; Non-small-cell-lung-cancer;

D O I：

10.2165/11207680-000000000-00000

中图分类号：

学科分类号：

摘要：

Crizotinib is an inhibitor of receptor tyrosine kinases (including anaplastic lymphoma kinase ALK).Oral crizotinib 250mg twice daily was associated with clinically meaningful response rates in two noncomparative trials (phase I and phase II) in patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC).In the phase I trial (median duration of treatment of 32 weeks) and phase II trial (median duration of treatment of 22 weeks), the objective response rate in crizotinib recipients was 61 and 50, respectively, and the median duration of response was 48.1 and 41.9 weeks, respectively. Responses were rapid, with the majority of patients achieving an objective response within the first 8 weeks of treatment.Crizotinib was generally well tolerated, with most adverse reactions being grade 1 or 2. The most commonly reported treatment-related adverse reactions were vision disorder, gastrointestinal disorders and oedema. © 2012 Adis Data Information BV. All rights reserved.

引用

页码：99 / 107

页数：8

共 21 条

[1]

Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S.-I., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., Mano H., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 7153, pp. 561-566, (2007)

[2]

Wong D.W., Leung E.L., So K.K., Et al., The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS, Cancer, 115, 8, pp. 1723-1733, (2009)

[3]

Shaw A.T., Solomon B., Targeting anaplastic lymphoma kinase in lung cancer, Clin Cancer Res, 17, 8, pp. 2081-2086, (2011)

[4]

Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., MacNeill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J., Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer, Cell, 131, 6, pp. 1190-1203, (2007)

[5]

Takeuchi K., Choi Y.L., Togashi Y., Et al., KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistrybased diagnostic system for ALK-positive lung cancer, Clin Cancer Res, 15, 9, pp. 3143-3149, (2009)

[6]

Soda M., Takada S., Takeuchi K., Et al., A mouse model for EML4-ALK-positive lung cancer, Proc Natl Acad Sci U S A, 105, 50, pp. 19893-19897, (2008)

[7]

Inamura K., Takeuchi K., Togashi Y., Et al., EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset, Mod Pathol, 22, 4, pp. 508-515, (2009)

[8]

Chiarle R., Voena C., Ambrogio C., Et al., The anaplastic lymphoma kinase in the pathogenesis of cancer, Nat Rev Cancer, 8, 1, pp. 11-23, (2008)

[9]

Christensen J.G., Zou H.Y., Arango M.E., Et al., Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma, Mol Cancer Ther, 6, 12 PART. 1, pp. 3314-3322, (2007)

[10]

McDermott U., Iafrate A.J., Gray N.S., Et al., Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors, Cancer Res, 68, 9, pp. 3389-3395, (2008)

← 1 2 3 →